Sign Up to like & get recommendations! 1
Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2677
Abstract: Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "World Journal of Surgery"
DOI: 10.1007/s00268-020-05503-4
Abstract: Background Unresectable pancreatic cancer (UR-PC) has a poor prognosis. Although conversion surgery has been considered a promising strategy for improving prognosis in UR-PC, the clinical benefit offered to patients with UR-PC remains controversial. This study… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04174-1
Abstract: Purpose We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Methods We enrolled patients aged 20 years or older… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4043-2
Abstract: BackgroundNeurolytic celiac plexus block (NCPB) is a safe and effective method for reducing abdominal cancer pain. However, the analgesic efficacy of NCPB is not always guaranteed. The aim of this retrospective study was to identify… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Japanese Journal of Radiology"
DOI: 10.1007/s11604-018-0743-2
Abstract: PurposeThe purpose of this study is to investigate the dose distribution of proton beam therapy (PBT) using a concomitant boost technique for unresectable pancreatic cancers.Materials and methodsThis simulation study involved 36 patients with unresectable pancreatic… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Clinical radiology"
DOI: 10.1016/j.crad.2019.07.014
Abstract: AIM To investigate the incidence and clinical characteristics of acute pancreatitis following percutaneous insertion of metallic biliary stents in patients with unresectable pancreatic cancer. The clinical efficacy of metallic stent insertion was also evaluated. MATERIALS… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Acta Oncologica"
DOI: 10.1080/0284186x.2017.1342863
Abstract: Abstract Background: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for unresectable pancreatic cancer, and is postulated to be more effective and less toxic than conventionally fractionated intensity modulated radiation therapy (IMRT). Material… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyac101
Abstract: Systemic chemotherapy plays important role in pancreatic cancer not only for palliative treatment of unresectable disease, but also for neoadjuvant and adjuvant treatment of resectable disease. Most clinical trials of systemic chemotherapy have been conducted… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pancreas"
DOI: 10.1097/mpa.0000000000001985
Abstract: OBJECTIVE The aim of the study was to clarify the association of skeletal muscle mass and the prognosis of unresectable pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine plus nab-paclitaxel (GnP). METHODS We included 124 unresectable… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Annals of Surgery"
DOI: 10.1097/sla.0000000000003651
Abstract: To the Editor: We read with great interest the article entitled ‘‘Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.’’ We would like to congratulate the authors for their insights… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "ANZ Journal of Surgery"
DOI: 10.1111/ans.16669
Abstract: Pancreatic ductal adenocarcinoma (PDAC) presents as unresectable disease in 80% of patients. Limited Australian data exists regarding management and outcome of palliative management for PDAC. This study aims to: (i) identify patients with PDAC being… read more here.